Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. 1991

J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
Cátedra de Farmacología, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, Argentina.

Serum concentrations of ticarcillin were measured serially over a period of 12h in a cross over trial involving 6 healthy adult ewes after intravenous and intramuscular (IM) administration of 40 mg ticarcillin per kg body weight. Probenecid (40 mg/kg) was also administered IM immediately before the IM administration of 40 mg/kg ticarcillin. Pharmacokinetic values after intravenous administration were: half-life of elimination (T 1/2 beta) = 0.90 +/- 0.09 h; volume of distribution at steady state (Vdss) = 456.8 +/- 106.6 ml/kg, total body clearance (CIB) = 614.5 +/- 81.2 ml/h/kg. Ticarcillin persisted in serum at greater than or equal to 1.5 micrograms/ml for 4 hours. Pharmacokinetic and bioavailability values after intramuscular administration were: half-life of absorption (T 1/2 ab) = 8.08 +/- 1.98 min; T 1/2 beta = 0.96 +/- 0.07 h. Peak serum concentration (Cmax) was 31.11 +/- 6.02 micrograms/ml at 0.50 h (Tmax), bioavailability (F) was 0.82 +/- 0.09. After ticarcillin was administered IM together with probenecid the T 1/2 ab was 33.9 +/- 13.7 min, the T 1/2 beta 2.66 +/- 0.65 h, Cmax = 44.87 +/- 5.58 at 1.33 +/- 0.44 h, and F = 1.25 +/- 0.23.

UI MeSH Term Description Entries
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012756 Sheep Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS. Ovis,Sheep, Dall,Dall Sheep,Ovis dalli
D013982 Ticarcillin An antibiotic derived from penicillin similar to CARBENICILLIN in action. BRL-2288,Tarcil,Ticar,Ticarcillin Disodium,Ticarpen,Ticillin,BRL 2288,BRL2288,Disodium, Ticarcillin

Related Publications

J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
June 1985, Journal of veterinary pharmacology and therapeutics,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
January 1980, Clinical therapeutics,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
March 1985, Journal of veterinary pharmacology and therapeutics,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
December 1984, Journal of veterinary pharmacology and therapeutics,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
January 1982, European journal of clinical pharmacology,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
January 1981, Clinical pharmacokinetics,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
February 1985, American journal of veterinary research,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
December 1992, The Journal of antimicrobial chemotherapy,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
January 1991, Developmental pharmacology and therapeutics,
J O Errecalde, and C E Lanusse, and O N Mestorino, and M F Landoni, and A L Soraci
January 1986, American journal of veterinary research,
Copied contents to your clipboard!